# Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma

> **NCT00725582** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 24 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** IMA-026
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00725582
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2009-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725582, "Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00725582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*